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Abstract Seven members of the murine caspase (mCASP) 
family were cloned and functionally characterized by transient 
overexpression: mCASP-1 (mICE), mCASP-2 (Ichl), mCASP-
3 (CPP32), mCASP-6 (Mch2), mCASP-7 (Mch3), mCASP-11 
(TX) and mCASP-12. mCASP-11 is presumably the murine 
homolog of human CASP-4. Although mCASP-12 is related to 
human CASP-5 (ICErei-III), it is most probably a new CASP-1 
family member. On the basis of sequence homology, the caspases 
can be divided into three subfamilies: first, mCASP-1, mCASP-
11 and mCASP-12; second, mCASP-2; third, mCASP-3, 
mCASP-6 and mCASP-7. The tissue distribution of the 
CASP-1 subfamily transcripts is more restricted than that of 
the CASP-3 subfamily transcripts, suggesting that the transcrip-
tional regulation of the CASP members within one subfamily is 
related, but is quite different between the CASP-1 and the 
CASP-3 subfamilies. Transient overexpression of each of the 
seven CASPs induced apoptosis in mammalian cells. Only two, 
mCASP-1 as well as mCASP-3, were able to process precursor 
interleukin (IL)-lß to biologically active IL-lß. In addition, 
mCASP-3 is the predominant PARP-cleaving enzyme in vivo. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Apoptosis or programmed cell death is an essential process 
during normal development and homeostasis of a multicellu-
lar organism [1-4]. Recently, genes involved in apoptosis of 
particular cell types in the nematode Caenorhabditis elegans 
have been characterized. Both positive effectors (CED-3 and 
CED-4) and a negative regulator (CED-9) have been identi-
fied [5,6]. Several human homologs of CED-3 and CED-9 
have been described, while so far a vertebrate homolog of 
CED-4 has not been found. The first identified mammalian 
homolog of CED-3 was interleukin- lß-converting enzyme 
(ICE [7,8]), a cysteine protease which processes inactive pro-
interleukin-lß (pIL-lß) to its biologically active form [9]. Re-
cently, several human (h) and murine (m) ICE or caspase 
(CASP) homologs have been cloned [10-12]. In the human 
system, CASP-1 (ICE [13]), CASP-2 (Ichl [14]), CASP-3 
(CPP32, Yama or apopain [15-17]), CASP-4 (TX, Ich2 or 
ICE r c l-II [18-20]), CASP-5 ( ICE r d - I I I or TY [20,21]), CASP-
6 (Mch2 [22]), CASP-7 (Mch3, ICE-LAP3 or CMH-1 [23-
25]), CASP-8 ( M A C H , F L I C E or Mch5 [26-28]), CASP-9 
(ICE-LAP6 [29]) and CASP-10 (Mch4 [26]) were identified. 
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In the mouse, only the molecular cloning of CASP-1 [30,31], 
CASP-2 (NEDD-2 or Ichl [32]) and CASP-11 (Ich3 [33]) has 
been reported to date. These CASP proteins constitute a new 
class of cysteine proteases, and transient overexpression of 
each of them caused apoptosis in mammalian or insect cell 
lines. 
Here we report on the molecular cloning and side-by-side 
comparison of seven mCASPs : mCASP-1 , mCASP-2, 
mCASP-3, mCASP-6, mCASP-7, mCASP-11 (mTX, 
mCASP-4) and mCASP-12. Transient overexpression experi-
ments in mammalian cells allowed us to assess the role of 
these cysteine proteases in apoptosis, pro-interleukin-lß proc-
essing, and poly(ADP-ribose) polymerase (PARP) cleavage. 
2. Materials and methods 
2.1. Cloning of mCASP cDNAs 
Degenerate oligonucleotides were synthesized with reference to two 
conserved regions of the CASP family, viz. [L,V][V,A][L,F,I]-
[L,M]SHG and [F,I][I,V]QACRG. 
The following degenerate sense primers were used: 
(A) T G C G A A T T C [ G , C , T ] T I G [ C , T ] I [ C , T , A ] T I [ T, C] T I T C -
I C A [ T , C ] G G ; 
(B) T G C G A A T T C [ G , C , T ] T I G [ C , T ] I [ C , T , A ] T I [ T , C ] T I A G -
[ C , T ] C A [ T , C ] G G ; 
(C) T G C G A A T T C [ G , C , T ] T I G [ C , T ] I [C, T , A] TIATG [T, A] -
[C ,G] I C A [ C , T ] G G ; 
and the following degenerate antisense primers: 
(R) T G C G A A T T C I C C [ A , T , G , C ] C [ G , T ] [G, A] CA [G, C, T, A ] -
G C [ T , C ] T G ; 
(N) TCGGGATCCIC[G,T][G, A] CAIGC [ T, C] TG [G, C, T, A] A -
[ T , C ] [ T , G , A ] A . 
The combinations of primer A and R, primer B and R, and primer 
C and R were taken for the first PCR amplification. Next, 2 jj.1 ali-
quots of the resulting products were amplified again with the same 
sense primer, but with primer N as an antisense primer. 1 ug of 
murine genomic DNA or 4 ng of a cDNA library derived from 
L929r2 were used as template. The products were analyzed on a 2% 
agarose gel. The isolated PCR products were cloned into a pGEM-T 
vector (Promega Biotec, Madison, WI). 1500 clones were further an-
alyzed by a combination of consecutive hybridizations and cycle se-
quencing of selected inserts on an ABI373A sequencer (Applied Bio-
systems, Foster City, CA). PCR clones showing significant amino acid 
homology with CASP-1 were selected and the inserts were used se-
quentially as probes to screen 4X105 colonies of an L929r2 cDNA 
library which were transferred to nylon membranes (HybondN; 
Amersham Life Science, Amersham, UK). Hybridization occurred 
under stringent conditions. 
The L929r2 cells used to construct a cDNA library [34] had been 
stimulated for 4 h with 1000 IU/ml of human tumor necrosis factor 
(TNF) and 10 |ig/ml cycloheximide. 
2.2. Plasmid construction for eukaryotic and in vitro expression 
One clone of each murine homolog was chosen to be subcloned into 
a pCAGGS eukaryotic expression vector [35] using routine recombi-
nant DNA techniques. The generated vectors are further referred to as 
pCAGGS-mCASP-x (x = 2, 3, 6, 7, 11 or 12). The human IL-lß 
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precursor (pIL-lß) gene was excised as an EcóRl fragment from an 
88.YH plasmid (a generous gift from Dr. J. DeLamarter, Glaxo In-
stitute for Molecular Biology, Geneva) and subcloned into pCAGGS 
to generate pCAGGS-pIL-lß. The same insert fragments were cloned 
into a Hindi- or .EcoRI-opened pGEMllzf(+) vector (Promega Bio-
tec) to generate pGEM-mCASP-x (x = 2, 3, 6, 7, 11 or 12) and 
pGEM-pIL-lß. mCASP-1 cDNA (pCAGGS-mCASP-1) was cloned 
from an EL4/c cDNA library constructed in pCAGGS. The Sfili 
Noti insert was bimAlNotl subcloned in pGEMHZf(+) to obtain 
pGEM-mCASP-1. TRADD cDNA was obtained by PCR from 
first-strand cDNA derived from human KYM cells and subcloned 
in pCDNAI (Invitrogen, San Diego, CA). pUT651 contains the 
gene coding for ßGal (Cayla, Toulouse, France). 
2.3. In vitro transcription/translation 
Coupled transcription/translation was performed using a TNT kit 
from Promega Biotec according to the manufacturer's recommenda-
tions. Plasmids derived from pGEMllzf(+) were used as a template 
for SP6 or T7 RNA polymerase. The reaction products were analyzed 
by SDS-PAGE and stored at — 70°C until needed. The autoprocessing 
activity of translated products was tested by adding 2 (J.1 of translation 
mixture to 18 |xl of TCE maturation buffer', containing 0.1% CHAPS, 
50 mM HEPES pH 7.5 (KOH), 1 mM EDTA, 10 mM DTT, 1 mM 
PMSF, 50 uM leupeptin and 20 ug/ul aprotinin, for 90 min at 37°C. 
2.4. Cell lines and transient transfections 
L929s is a TNF-sensitive murine fibrosarcoma. MCF7 is a human 
breast adenocarcinoma line. COS7 is a replication-defective SV40-im-
mortalized fibrosarcoma line derived from African green monkey kid-
ney cells. HeLa H21 is a human cervix carcinoma. Rati is a rat 
fibrosarcoma. HEK293 is a human embryonal kidney carcinoma. 
All cell lines were cultured in appropriate media using standard tissue 
culture procedures. L929s, MCF7, COS7 and HeLa H21 were rou-
tinely transfected using the calcium phosphate precipitation method 
[36]. HeLa H21 and Rati were also transfected with lipofectamin 
(Life Technologies, Paisley, UK) according to the manufacturer's in-
structions. A lipofectamin:plasmid DNA concentration ratio of 8:1 
was used. For both transfection methods cells were seeded the day 
before at 104 cells/96-well, 5X104 cells/24-well or 5X 105/6-well; a 
total amount of plasmid DNA of 200 ng/96-well, 600 ng/24-well or 
6 ug/6-well was added (50% pCAGGS-mCASP-x or TRADD, 25% 
pUT651, 25% pCAGGS-pIL-lß or empty pCAGGS). Cells were 
transfected for 6-12 h, washed and incubated for another 24 h before 
the XGal assay, or another 48 h before supernatant was collected and 
tested in a biological assay for IL-Iß. 
2.5. ßGa/ assay 
ßGal activity was visualized by fixing transfected cells with 0.2% 
glutaraldehyde and 2% formaldehyde in PBS(A) for 5 min at 4°C, 
followed by extensive washing. Cells were stained in PBS(A) contain-
ing 1 mg/ml XGal, 5 mM potassium ferricyanide, 5 mM potassium 
ferrocyanide, 2 mM MgCl2, 0.02% NP40 and 0.01% SDS. All blue 
cells in the well were counted. 
2.6. pIL-lß-processing assay 
Biologically active IL-Iß was determined using growth factor-de-
pendent D10(N4)M cells [37]. Cells were maintained in RPMI 1640 
medium supplemented with 10% FCS, 2 mM L-glutamine, 100 IU/ml 
penicillin G, 100 u.g/ml streptomycin, 1 mM sodium pyruvate, 5 mM 
ß-mercaptoethanol and 10% supernatant of phorbol ester-stimulated 
EL-4 cells as a source of IL-2, and 10% supernatant of phorbol ester-
stimulated P388D1 cells as a source of IL-1. The day before the assay, 
D10(N4)M cells were washed and transferred to culture containing 
only 10% EL-4 supernatant. The next day, cells were washed again 
and added to serial dilutions of IL-lß-containing samples (104 cells/ 
96-well), followed by incubation for 24 h at 37°C in a CO2 incubator; 
proliferation was quantified by [3H]thymidine incorporation (0.5 itCi/ 
well) for the last 6 h. Cells were harvested and incorporated 
[3H]thymidine was determined in a microplate scintillation counter 
(Packard Instrument Co., Meriden, CT). Samples were quantified 
according to a standard preparation of IL-Iß with a specific biological 
activity of 109 IU/mg (obtained from the National Institute for Bio-
logical Standards and Control, Potters Bar, UK). 
2.7. Northern blot analysis 
Multiple tissue Northern blot membranes of murine adult tissues 
were purchased from Clontech Laboratories (Palo Alto, CA). Each 
lane contained 2 |ig of poly(A)+ RNA. Sequential hybridization and 
stripping were performed according to the manufacturer's instruc-
tions. The human ß-actin control probe was also supplied by Clontech 
Laboratories. 
2.8. PARP cleavage assay 
5X105 HEK293 cells were transfected with 6 ug pCAGGS-
mCASP-x (x= 1, 2, 3, 6, 7, 11 or 12) or empty pCAGGS vector by 
calcium phosphate coprecipitation. The transfection efficiency was 
45% as determined by ßGal expression in pUT651 -transfected cells. 
31 h after transfection, the cells were lysed in lysis buffer, containing 
50 mM Tris pH 8.0, 300 mM NaCl, 5 mM EDTA, 15 mM MgCl2, 1% 
NP40, 50 ug/ml PMSF, 10 ug/ml aprotinin and 10 ug/ml leupeptin. 90 
Ug of total protein was loaded on 12.5% SDS-PAGE and Western 
blot analysis performed using a CI-IO anti-PARP antibody (a kind 
gift from Dr. W. Earnshaw, Johns Hopkins School of Medicine, Bal-
timore), which detects the 85 kDa cleavage product of PARP. 
3. Results and discussion 
3.1. Cloning of seven mCASPs 
In an attempt to identify all mCASPs, we have used family 
PCR both on genomic DNA and on cDNA. Two largely 
conserved domains in the sequence of CED-3 and the murine 
and human counterparts of CASP-1 and CASP-2 were se-
lected to construct degenerate primers: [L,V][V,A][L,F,I] 
[L,M]SHG and [F,I][V,I]QACRG (Fig. 1A). These two do-
mains are located within one exon in the murine casp-1 gene 
[38], the human casp-1 gene [39] and the ced-3 gene [7]. We 
used both murine genomic DNA as well as murine cDNA 
derived from L929r2 cells as PCR template: the former in 
order to isolate CASPs independent of cell-specific expression 
patterns, the latter with the intention not to miss homologs 
with an exon-intron boundary between the SHG and 
QACRG boxes of homology. The nucleotide sequence of 
the cloned PCR products revealed seven different murine 
members of the CASP family, including the already reported 
mCASP-1 [30,31], mCASP-2 [32] and mCASP-11 [33]. Re-
markably, PCR both on genomic DNA as well as on 
L929r2 cDNA revealed the same seven CASPs. Obviously, 
the murine counterparts of CASP family members in which 
the regions of the degenerate primers are not completely con-
served, were missed using this cloning procedure, e.g. CASP-8, 
CASP-9 and CASP-10, in which the QACRG box is not con-
served [26,27,29]. The inserts of the seven identified PCR 
clones, except for the mCASP-1 fragment, were used as a 
probe to isolate the corresponding full-length cDNAs from 
an L929r2 cDNA library. mCASP-1 had been isolated previ-
Fig. 1. Alignment of amino acid sequences of murine members of the CASP family and their relationships. (A) Deduced amino acid sequences 
for hCASP-1 [13] and mCASP-1, mCASP-11, mCASP-12, mCASP-7, mCASP-3, mCASP-6 and mCASP-2. The sequences were aligned using 
the Genetics Computer Group (Madison, WI) PILEUP algorithm (gap weight = 3.0; gap length weight = 0.1). Identical and similar amino acids 
are boxed in black and grey, respectively. Conserved QACRG and SHG boxes used for designing degenerate primers are shown by arrows. 
Leugg of mCASP-2 is italicized. Amino acids that align with the residues of hCASP-1 forming the binding pocket for PI Asp, are indicated by 
♦ (Argi79, Gln283, Arg34i and Ser347); amino acids involved in catalysis are indicated by • (HÌS237, Gly238 and Cys28s). A putative protein kin-
ase C phosphorylation site is marked by ■. (B) Phylogenetic comparison of hCASPs and mCASPs originating from a CED-3-like ancestor. 
The alignment was achieved as described above and was used to generate the dendrogram by the CLUSTAL W program [50]. The CASP-3 
subfamily (red) and hCASP-9 (purple) are weakly related to each other. The CASP-2 subfamily is shown in green, the CASP-1 subfamily in 
blue. 
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Fig. 2. mRNA expression pattern of mCASPs. Murine, multiple, 
adult tissue Northern blots were hybridized sequentially with 
mCASP-11, mCASP-1, mCASP-12, mCASP-2, mCASP-7, mCASP-
3, mCASP-6 and human ß-actin probes. The size of the hybridizing 
bands is indicated in kb. (1) mCASP-1 subfamily, (2) mCASP-2 
subfamily, (3) mCASP-3 subfamily. 
ously from an EL4/c cDNA library [40]. For each murine 
homolog one clone, containing the largest open reading 
frame, was retained for further characterization. These 
cDNA clones were identified as coding for the presumed mur-
ine homologs of hCASP-2, hCASP-3, hCASP-4 (mCASP-11), 
hCASP-6 and hCASP-7 (Fig. 1A). The translated open read-
ing frames are 91.5, 92.5, 73.5, 96 and 90.5% similar, and 86, 
86.5, 60, 90.5 and 82% identical, respectively, to their human 
counterparts. It should be noted that the homology between 
hCASP-4 (TX) and mCASP-11 (Ich3) is as significant as be-
tween human and murine CASP-1, which have 75% similarity 
and 62%o identity [30,31]. In addition, amino acid alignment 
between hCASP-4 and mCASP-11 shows only a 4 amino acid 
gap located in the prodomain (data not shown). Moreover, we 
were also able to show functional homology, since both 
hCASP-4 and mCASP-11 cleave CASP-1 ([18]; Van de Craen 
et al., in preparation). Consequently, we conclude that 
mCASP-11 is the counterpart of hCASP-4, but the recom-
mendation is to refer to this sequence as mCASP-11 (Drs. J. 
Yuan and N.A. Thornberry, personal communication on be-
half of the nomenclature committee). On the other hand, 
mCASP-12 has only 62% similarity and 44.5% identity to 
hCASP-5; amino acid alignment of these two homologs re-
veals several gaps (data not shown). Hence, it seems that 
mCASP-12 is not the murine counterpart of hCASP-5, but 
constitutes a new CASP-1 subfamily member. Our cloned 
mCASP-2 is identical to mNEDD-2 [32], except for the insert 
of an extra Leu at position 88 (Fig. 1A). 
3.2. Sequence comparison of CASPs 
The multiple sequence alignment for hCASP-1, mCASP-1 
and the newly cloned mCASPs is shown in Fig. 1A. Residues 
Argi7g, Gln283, Arg34i and Ser347 constitute the Asp-binding 
pocket in hCASP-1 [41,42] and are conserved in all cloned 
members of the CASP family, except for mCASP-12 in which 
Arg341 is conservatively replaced by Lys. This makes mCASP-
12 the only known CASP family member, including the re-
lated hCASP-5, with an amino acid substitution at this im-
portant position and argues again in favor of mCASP-12 
being a new CASP-1 subfamily member. The residues in-
volved in catalysis, HÌS237, Gly238 and Cys285 of hCASP-1, 
are conserved in all family members. The dendrogram in 
Fig. IB shows that the CASP protein family comprises three 
subfamilies. The CASP-3 subfamily consists of h/mCASP-3, h/ 
mCASP-6, h/mCASP-7, hCASP-8 and hCASP-10. This sub-
family, especially h/mCASP-6, displays the highest homology 
with CED-3, which agrees with the presumed central role of 
CASP-3-like proteases in different pathways of apoptosis 
[17,43]. Presumably, also hCASP-9 belongs to the CASP-3 
subfamily, but, depending on the type of phylogenetic analy-
sis, it can also be related to the second subfamily, the CASP-2 
subfamily. The latter consists of human and murine CASP-2. 
A characteristic feature is the absence of a putative protein 
kinase C phosphorylation site SXR (Ser33g of hCASP-1), 
which is conserved in all other CASPs. The third subfamily, 
viz. CASP-1, consists of h/mCASP-1, hCASP-4/mCASP-ll, 
hCASP-5 and mCASP-12. This subfamily is characterized 
by a wider amino acid sequence divergence between the hu-
man and murine homologs ( < 75% similarity as compared to 
> 90% similarity for the other two subfamilies). This might 
indicate that CASP-1 subfamily members do not fulfill such a 
central role as the CASP-3 subfamily. In this respect it may be 
noted that CASP-1-deficient mice are quite healthy, and their 
cells, except for Fas-induced apoptosis of thymocytes, are not 
affected in their capacity to undergo cell death [44,45]. 
3.3. Tissue distribution of mCASP cDNAs 
The expression of the different murine casp gene family 
members was examined by Northern blot analysis under strin-
gent hybridization conditions. The full-length cDNA clones 
were used as a probe for sequential hybridization of a multiple 
tissue Northern blot (Fig. 2). The sizes of the predominantly 
hybridizing transcripts were consistent with the length of the 
cloned cDNAs for mCASP-1 (1322 bp), mCASP-2 (3463 bp), 
mCASP-6 (1262 bp), mCASP-7 (2371 bp), mCASP-11 (1340 
bp) and mCASP-12 (2262 bp), except for the mCASP-3 tran-
script which was approx. 1300 bp larger than the cDNA clone 
(1297 bp); presumably, the cDNA clone isolated lacked most 
of the 3'-UTR sequences. The weakly hybridizing, larger tran-
scripts could correspond to incompletely or alternatively proc-
essed mRNAs, while some smaller species could be alterna-
tively spliced isoforms or degradation products (results not 
shown). Cross-hybridization under the conditions used is un-
likely, but cannot be completely excluded. 
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Fig. 3. In vitro transcription and translation of mCASPs (pGEMllzf(+)-based vectors) in reticulocyte lysate in the presence of [35S]methionine 
for 90 min at 30°C. 2 ul of this mixture was loaded on an SDS-polyacrylamide gel. Molecular mass markers are indicated on the left. 
As regards the mRNA tissue distribution (Fig. 2 and Table 
1), mCASP-11 mRNA was most expressed in lung, weaker in 
spleen and heart, and little in liver, skeletal muscle, kidney 
and testis. No message could be detected in the brain. Tran-
scripts of mCASP-7 were prominent in most tissues, but es-
pecially in liver, lung, kidney and heart. The 2.5 kb mCASP-
12 transcript was most abundant and was mainly expressed in 
skeletal muscle and lung, and moderately expressed in the 
other tissues analyzed. It may be noted that the potential 
mCASP-12 counterpart, hCASP-5, is only clearly expressed 
in lung, liver, placenta and pancreas [20]. Moreover, 
hCASP-4 (mCASP-11 counterpart) has a comparable expres-
sion pattern to mCASP-11 and hCASP-8 (hICErei-III) [20], 
while the tissue distribution of mCASP-11 and mCASP-12 
expression is not related (Table 1). This suggests once more 
that mCASP-12 is not the murine homolog of hCASP-5, while 
mCASP-11 is presumably the murine counterpart of hCASP-
4. mCASP-3 mRNA (2.5 kb) is mostly expressed in spleen, 
kidney, lung and liver, but also the other tissues reveal rela-
tively high levels. mCASP-6 mRNA is clearly present in all 
tissues and the expression is especially high in liver, lung, 
kidney, testis and heart. mCASP-2 (4 kb) is expressed in all 
Table 1 
Distribution of CASP mRNA in murine and human tissues 
mCASP-11 (1.5 kb) 
hCASP-4 (1.5 kb) [19] 
mCASP-1 (1.45 kb) 
hCASP-1 (1.5 kb) [19] 
mCASP-12 (2.5 kb) 
hCASP-5 (1.5 kb) [20] 
mCASP-2 (4 kb) 
hCASP-2 (4 kb) [14] 
mCASP-7 (2.5 kb) 
hCASP-7 (2.4 kb) [23,24] 
mCASP-3 (2.6 kb) 
hCASP-3 [15,24] 
mCASP-6 (1.4 kb) 
hCASP-6 (1.4 kb) 
Heart 
++ 
++ 
+ 
++ 
+ 
+ 
++ 
++ 
+++ 
+++ 
+++ 
+++ 
+++ 
ND 
Brain 
-
+ 
+ 
++ 
++ 
+ 
+ 
++ 
++ 
+ 
ND 
Spleen 
+++ 
++++ 
+++ 
++++ 
+ 
ND 
++++ 
ND 
++ 
+++ 
++++ 
+++ 
++ 
ND 
Lung 
++++ 
+++ 
+++ 
++++ 
++++ 
+++ 
++++ 
+++ 
++++ 
++++ 
++++ 
++++ 
++++ 
ND 
Liver 
+ 
++ 
+ 
++ 
+ 
++ 
++ 
+++ 
++++ 
+++ 
++++ 
+++ 
++++ 
ND 
Skeletal muscle 
+ 
+ 
+ 
+ 
++++ 
+ 
+ 
++ 
++ 
++++ 
++ 
++++ 
+ 
ND 
Kidney 
+ 
+ 
+ 
+ 
+ 
+ 
+++ 
+++ 
+++ 
+++ 
++++ 
+++ 
+++ 
ND 
Testis 
+ 
+ 
+ 
+ 
+ 
ND 
++ 
ND 
++ 
++ 
+ 
++ 
+++ 
ND 
++++, very strong; +++, strong; ++, moderate; +, low; -, not detectable expression; ND, not determined. Data for the murine system are from 
results shown in Fig. 2; data for the human system are from the references mentioned in the first column. 
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Fig. 4. mCASP-mediated induction of apoptosis by transient overexpression in mammalian cell lines. HeLa and Rati cells were cotransfected 
in 24-well plates with pUT651, containing ßGal, and pCAGGS-mCASP-x (x= 1, 2, 3, 6, 7, 11 or 12), TRADD or empty pCAGGS as control. 
24-36 h after transfection, the cells were stained with XGal and counted. The ordinate indicates the number of blue cells counted in each well 
for HeLa and Rati. The data are representative of three independent experiments. The relative counting variation was < 10%. 
tissues, but mainly in spleen and lung. mCASP-1 hybridiza-
tion revealed a band of 1.45 kb, mainly in spleen and lung. 
An important conclusion which can be drawn from Table 1, 
is that, except for mCASP-12 and hCASP-5, discussed above, 
and for h/mCASP-6 (where no data are available for the hu-
man system), there is a remarkable agreement in mRNA 
abundance of the various homologs in different human and 
murine tissues; this suggests a similar function and regulation. 
Furthermore, it may be noted that the tissue distribution of 
the CASP-1 subfamily transcripts, on the one hand, and the 
CASP-3 subfamily transcripts, on the other hand, are quite 
different. In general, the former have a restricted expression 
pattern, mainly confined to spleen and lung, tissues with im-
portant immune functions, and are only moderately expressed 
in the other tissues examined. Members of the latter subfamily 
have a much broader mRNA expression pattern. This could 
indicate that the transcriptional regulation of CASPs within 
one subfamily is related, but is quite different between the 
CASP-1 and CASP-3 subfamilies. This suggests that tran-
scription of CASP-1 subfamily members is mainly controlled 
by other transcription factors than in the case of the CASP-3 
subfamily members. In this respect, it has been reported that 
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Fig. 5. In vivo cleavage of human pIL-lß by cotransfection with mCASPs. The plasmids pCAGGS-mCASP-x 0 = 1 , 2, 3, 6, 7, 11 or 12) or 
empty pCAGGS were cotransfected with pCAGGS-pIL-lß in MCF7, COS7, L929sA or HeLa cells in 96-well microtiter plates. 48 h after 
transfection, the concentration of secreted IL-Iß was determined in a DIO bioassay. The left F-axis indicates IL-1 processing in MCF7 and 
COS7 cells (transfection efficiencies of 26 and 17%, respectively), the right 7-axis in L929s and HeLa cells (transfection efficiencies <2%). The 
experiments were performed in triplicate. 
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Fig. 6. In vivo cleavage of PARP by mCASPs. HEK293 cells were transfected with pCAGGS-mCASP-x (x= 1, 2, 3, 6, 7, 11 or 12) or empty 
pCAGGS vector (transfection efficiency of 45%). 31 h later, cells were lysed and proteins analyzed by SDS-PAGE (90 |ig total protein per 
lane). After Western blotting, cleavage of endogenous PARP was analyzed by means of anti-PARP antibody (CI-10), which revealed an 85 
kDa-speciflc degradation product. 
IRF-1, an IFN- and TNF-inducible transcription factor, con-
trols the expression of CASP-1 and might in this way play a 
role in inflammation [46]. 
3.4. In vitro transcription!translation 
Fig. 3 shows the [35S]methionine-labeled in vitro transcrip-
tion/translation products of the murine cDNA clones coding 
for the CASP precursors. Translation of mRNA from 
mCASP-1 (45.6 kDa), mCASP-11 (42.7 kDa), mCASP-7 
(35.5 kDa), mCASP-12 (47.8 kDa), mCASP-3 (31.5 kDa), 
mCASP-6 (31.5 kDa) and mCASP-2 (47 kDa) gave rise to 
products of a size expected on the basis of the cDNA sequen-
ces (mentioned in brackets). Lower molecular weight bands 
were presumably due to internal initiation and/or premature 
termination. No degradation was observed during the in vitro 
synthesis and no obvious changes in molecular weight pat-
terns were detectable after further incubation for 1.5 h in 
'ICE maturation buffer' (results not shown). Hence, we could 
conclude that, at the enzyme concentration examined, no au-
toprocessing occurred. It may be noted that in vitro tran-
scribed and translated CED-3 did show autoprocessing activ-
ity under similar assay conditions [47]. 
3.5. All mCASPs induce apoptosis in transfected cells 
In order to determine the apoptotic capacity of mCASPs, 
different cell lines were transiently transfected. To this end, 
the aforementioned CASP cDNAs were cloned in a pCAGGS 
expression vector [35]. The extent of apoptosis in the trans-
fected cells was quantified by means of a cotransfected plas-
mid containing a ßGal reporter gene. The extent of cell death 
in the transfected population was measured by the decrease in 
number of surviving ßGal-expressing cells, using XGal as an 
indicator substrate. As a positive control for the induction of 
apoptosis, an expression vector coding for the TNF p55 re-
ceptor-associated death domain (TRADD) [48] was cotrans-
fected. As a negative control, the empty pCAGGS vector was 
used. In the cell lines tested, transient overexpression of the 
TRADD-containing plasmid caused a profound reduction in 
the number of ßGal-expressing cells as compared to the neg-
ative controls. Transient overexpression of mCASP-1 and all 
murine homologs in HeLa and Rati cells resulted in a clear 
reduction in the number of XGal-positive cells (Fig. 4 and 
unpublished results), although the extent of apoptosis varied 
from experiment to experiment. Since precursor CASP genes 
were used for these experiments, these results mean either that 
the full-length product was active, or if not, that the trans-
fected cells were capable to generate processed, active forms. 
Remarkably, and in contrast to TRADD overexpression, 
transient transfection of CASPs in L929s cells induced little 
or no apoptosis (data not shown). 
3.6. pIL-lfi is mainly processed by mCASP-1, but also by 
mCASP-3 
CASP-1 was discovered originally as the protease responsi-
ble for processing of pIL-lß [9,13]. We examined, by transient 
cotransfection of the CASP-containing expression plasmids 
with a human pIL-lß-coding vector, whether other CASPs 
in addition to CASP-1 were able to cleave inactive pIL-lß 
into mature IL-lß. An IL-lß-processing activity by transient 
cotransfection may be due to direct processing by the cotrans-
fected CASP or can be explained by CASP-mediated activa-
tion of endogenous CASP-1. Four cell lines with different 
transfection efficiency were used, viz. MCF7, COS7, HeLa 
and L929s. Secreted mature IL-lß was quantified in a bio-
assay using DIO cells [37] (Fig. 5). As expected, cotransfection 
with mCASP-1 expression vector resulted in a high level of 
biologically active mature IL-lß. Except for mCASP-3 (see 
below), none of the other mCASPs were able to induce pIL-
lß processing. This also means that neither of the other 
CASPs could activate sufficient levels of endogenous CASP-
1 or CASP-3 to result in detectable amounts of IL-lß. Cells 
transfected with an mCASP-3 expression vector clearly re-
sulted in mature IL-lß levels in the four cell lines examined, 
at a level of 10-30% of the amounts obtained with mCASP-1. 
In agreement with these findings, we could show in vitro that 
only bacterially expressed mCASP-1 and, to a lesser extent, 
mCASP-3, were able to process pIL-lß to the expected 28 and 
17 kDa fragments; the other bacterial mCASP preparations 
did not exhibit this activity (Van de Craen et al., in prepara-
tion). As hCASP-3-mediated cleavage of pIL-lß has not been 
demonstrated [16], this indicates that the substrate specificity 
between human and murine CASP counterparts might be dif-
ferent. Kamens et al. [19] reported in vitro cleavage of pIL-lß 
by hCASP-4; however, two other groups could not confirm 
this result [18,20]. 
3.7. mCASP-3 is the predominant PARP-cleaving CASP in 
vivo 
Cleavage of PARP has frequently been reported to correlate 
with apoptosis [16,17]. In some cell lines, inactivation of this 
repair enzyme may even directly contribute to cell death [49], 
although mice lacking PARP develop normally and no effects 
on death pathways are in evidence [14]. mCASP-x expression 
plasmids ( x = l , 2, 3, 6, 7, 11 or 12) were transiently trans-
68 
fected in HEK293 and endogenous PARP cleavage was exam-
ined by Western blotting. Fig. 6 shows that especially in cells 
transfected with mCASP-3, PARP was clearly cleaved releas-
ing the characteristic 85 kDa fragment, suggesting that 
mCASP-3 is the main PARP-cleaving enzyme. 
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